Hyaluronic Acid Market Size Worth $16.6 Billion By 2027

The global hyaluronic acid market size is expected to reach USD 16.6 billion by 2027, expanding at a CAGR of 8.1%, according to a new report by Grand View Research, Inc. Factors such as increasing concern of population regarding chemicals, desire to get quick and evident results, and shorter recovery time are high impact rendering drivers of this market.

The market is evolving rapidly due to the increasing adoption of aesthetic procedures in developed and developing regions. Increasing use of hyaluronic acid surfaces in cardiovascular implants, such as stents and vascular grafts, for improving the compatibility coupled with growing awareness about anti-aging products is fueling the growth. The efficacy and evident results of hyaluronic acid based dermal fillers are attracting this population base.

The global increase in population also results in an increased demand for antiaging cosmetic and aesthetic treatments. Owing to its distinctive viscoelastic and moisturizing properties coupled with lower toxicity levels, hyaluronic acid products are directly affected by growing demand for minimally invasive antiaging solutions. The minimal adverse effects, lower pain, shorter recovery time, and lesser postsurgical complications make minimally invasive surgeries significantly attractive.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/hyaluronic-acid-market

Further key findings from the study suggest:

The osteoarthritis segment held the largest share in 2019. In 2013, more than 27 million people were suffering from osteoarthritis. Viscosupplements are gaining popularity as a cure in pain management. Use of hyaluronan as a treatment for osteoarthritis has been approved by the U.S. FDA in 1997 and has gained substantial market share
The rising obesity resulting in osteoarthritis and joint pain has increased the demand for hyaluronic acid injections as treatment. With the prevailing consumer trend, which favors convenience over higher costs, companies such as Genzyme (Sanofi-Aventis) and Zimmer have launched single-injection products. The 2014 FDA approval for single-injection treatment “MONOVISC” is expected to further fuel the growth of the single-injection product segment
Cosmetic surgeries are booming with approximately 14 million minimally invasive procedures performed every year. In 2013, hyaluronan-based facial fillers received FDA approval, which is used in corrective measures, anti-aging procedure, and filling fine lines. These dermal fillers constitute a large share in these procedures and witnessed 8% growth in the year 2014
Growing preference for short-treatment regimens, even though high priced, and growing prevalence of target diseases, such as osteoarthritis, are high impact rendering factors that can be attributed for the large share of this region. In 2019, the most lucrative applications of hyaluronic acid in the North American region were in the form of dermal fillers and viscosupplements for management of osteoarthritis
Hyaluronic acid market in Asia Pacific region is anticipated to emerge as the fastest growing region during the forecast period. The growing geriatric population in China and Japan provides a large customer base for anti-aging products and services. Increasing awareness about applications of hyaluronan and its efficacy fuels the demand. In addition, stabilizing economies leaves the middle-class population with surplus money to spend on these procedures
The industry is presently dominated by key participants such as F. Hoffmann-La Roche Ltd.; Seikagaku Corporation; Galderma S.A; Sanofi (Genzyme); Anika Therapeutics Inc.; Salix Pharmaceuticals; Zimmer Holdings Inc.; Allergan Inc.; Ferring Pharmaceuticals, Inc.; and Smith & Nephew Plc.

Vascular Grafts Market Size Worth $3.30 Billion By 2026

The global vascular grafts market size is projected to reach at USD 3.30 billion by 2026 expanding at a CAGR of 6.4%, according to a report by Grand View Research, Inc. Endovascular stent grafts dominated the market in 2018 and is expected to be the second fastest-growing segment over the forecast period. Increasing prevalence of cardiovascular aneurysms is the leading cause of rise in demand for endovascular stent grafts. Low levels of physical activity, sedentary lifestyle, and substance abuse are some of the key factors leading to the high prevalence of renal and Cardiac Diseases (CVDs) globally. The impact of these factors is especially high in developed economies, such as North America and Europe. However, it is expected to shift towards emerging regions, such as Asia Pacific and Latin America, owing to changing demographics.

Key factors attributed to higher impact in these countries are increasing prevalence of aforementioned diseases in geriatric population, rising disposable income, and changing lifestyle patterns. Polytetrafluoroethylene (PTFE) raw material segment led the global market in 2018 with a revenue of USD 710.3 million. The segment is anticipated to expand at the fastest CAGR over the forecast period on account of PTFE graft’s advantages, such as protection against delamination and minimal blood loss. Asia Pacific is expected to be the fastest-growing market with a CAGR of 7.5% over the forecast period due to increasing public and private healthcare expenditure and availability of healthcare insurance across urban and rural centers.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/vascular-graft-market

Further key findings from the study suggest:

Endovascular stent grafts led the market in 2018 as a result of increased prevalence of cardiac aneurysms caused due to sedentary lifestyle and other occupational factors
PTFE grafts led the raw materials segment in 2018 owing to their advantages, such as minimal blood loss and maximum protection against delamination
Moreover, technological advancements in PTFE-based products is anticipated to drive the segment further
North America was the dominant regional market with a revenue of USD 620.9 million owing to high prevalence of CVDs and kidney diseases
The region is projected to maintain the dominance in future due to the presence of advanced healthcare facilities and reimbursement policies
Some of the key companies in this market include Medtronic, plc; LeMaitre Vascular Inc.; Terumo Corp.; Getinge AB; W.L. Gore and Associates, Inc.; and Cook Medical, Inc.
These companies focus on technological innovations, new product launches, and regional expansion to gain a competitive edge

Automotive Electronic Control Unit Market Worth $84.29 Billion By 2025

The global automotive electronic control unit market size is expected to reach USD 84.29 billion by 2025, growing at a 4.4% CAGR over the forecast period, according to a study conducted by Grand View Rese0arch, Inc. The increasing demand for hybrid and luxury vehicles, rising deployment of infotainment systems, and growing preference for ADAS and automated safety systems are fueling the demand for automotive electronic control units (ECUs). Additionally, a growing number of functionalities to control several electronic components in the vehicle such as, dashboard instruments, engine, telematics, and powertrain, has also resulted in significant growth in the average number of ECUs used per vehicle.

Moreover, the governments and regulatory bodies are mandating the installation of several safety systems in a vehicle, such as adaptive cruise control, adaptive front lighting, and anti-lock braking system, among others, to increase road safety. Recently, the AUTOSAR Alliance has been formed to standardize the approach of the designing and developing of layers between ECU hardware and application software. Additionally, in April 2016, the European New Car Assessment Programme (NCAP) was launched to reduce the risk of accidents by mandating the integration of lane-departure warning and anti-lock braking systems in vehicles during their production phase. This is anticipated to make the integration of hardware and software more scalable and flexible.

Furthermore, the automotive ECU market directly depends upon the automotive production across the globe. Thus, the increasing automotive production across emerging economies would fuel the demand for automotive ECUs over the forecast period. Several government initiatives to mandate the installation of advanced safety systems in vehicles, coupled with the growing preference of consumers for luxury and hybrid vehicles are the key factors boosting the research & development spending on automotive ECUs. For instance, In October 2017, NXP Semiconductors N.V. revealed NXP S32 platform, an all-new control and compute concept for electric, autonomous and connected cars.

The Asia Pacific region dominated the market in 2018, a trend that is expected to continue over the forecast period. This is attributed to the significant investments in the automotive industry in emerging countries, such as China, South Korea, Japan, and India. Additionally, the Chinese market is estimated to reach USD 36.65 billion by 2025, growing at a CAGR of 9.5% from 2019 to 2025. Continuous technological innovations to reduce the ECU count per vehicle is also expected to create substantial opportunities in the Asia Pacific region.

The North American market is projected to expand at a considerable CAGR over the forecast period owing to several regulations and declarations made by the governments in the region to positively influence the demand for electric vehicles. For instance, the Californian government has set up a target of reaching 1.5 million zero-emission vehicles, thus boosting the regional demand.

Some of the key players operating in the market are Altera (Intel Corporation), Autoliv Inc., Continental AG, Delphi Technologies, Denso Corporation, Hyundai Mobis, NXP Semiconductors N.V., Robert Bosch GmbH, Valeo Inc., and ZF Friedrichshafen AG, among others. The global automotive ECU market is consolidated with the presence of a few players holding a majority share of the market.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/automotive-ecu-market

Further key findings from the report suggest:

The ADAS & safety systems application segment is anticipated to dominate the automotive electronic control unit market owing to stringent government regulations and rising consumer awareness pertaining to safety features in vehicles. The segment is estimated to reach USD 27.6 billion by 2025.
The Internal Combustion Engine (ICE) vehicles segment is estimated to hold a majority share of the market owing to the increasing production of vehicles in emerging economies.
The 32-bit segment held the largest market share of 91.0% in 2018. This share is expected to decline over the forecast period due to the rising demand for 64-bit ECUs to integrate advanced electronic functions in the vehicle.
The passenger car segment held the largest market share of 86.9% in 2018. This share is estimated to increase over the forecast period owing to the growing consumer preference for luxury and hybrid vehicles with advanced electronic and safety systems.
The Asia Pacific regional market is estimated to account for 62.8% of the overall automotive ECU industry in 2018, owing to the increasing production of vehicles in emerging economies, such as China, India, South Korea, and so on.
Prominent market players include Autoliv, Inc., Delphi Technologies, Denso Corporation, Robert Bosch GmbH, ZF Friedrichshafen AG.

Aesthetic Medicine Market Worth $103.4 Billion By 2026

The global aesthetic medicine market size is expected to reach USD 103.4 billion by 2026, exhibiting a CAGR of 8.9% during the forecast period, according to a new report by Grand View Research, Inc. Some key market drivers are rise in aging population, disposable income, and awareness about the efficacy of aesthetic treatments.

People aged between 25 and 65 years have prominent aging signs, such as wrinkles, fine lines, and dark spots. Rise in geriatric population is likely to boost the demand for aesthetic medicine due to significant rise in the number of target consumers. Moreover, the need for improved aesthetics in the working class population is likely to drive the demand over the forecast period. Improving employment rate, especially in the emerging markets, is anticipated to drive the demand for aesthetic medicine over the forecast period.

However, the presence of stringent regulatory framework to ensure product safety and efficacy is one of the primary factors limiting growth of the global aesthetic medicine market. Lack of skilled professionals required to perform surgical and minimally invasive procedures coupled with the growing overall treatment cost, is expected to hinder the market growth in the forthcoming years.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/medical-aesthetics-market

Further key findings from the report suggest:

Non-invasive procedures segment is expected to maintain its dominance throughout the forecast period. Growing preference for minimally or non-invasive cosmetic surgeries over invasive cosmetic surgeries attributed to various factors, such as lower costs, minimal trauma and incision, faster recovery, and low risk of complications is anticipated to fuel the segment growth
Botox injections, chemical peels, and soft tissue fillers are some of the most frequently performed non-invasive procedures to address some common issues, such as wrinkles, pigmentation, vascular conditions, loss of skin tone, and dull skin
Breast augmentation and nose reshaping in the invasive procedures segment are anticipated to witness rapid growth in the forthcoming years owing to availability of a rising number of advanced technologies and skilled surgeons
Asia Pacific is anticipated to witness rapid growth over the forecast period, owing to the presence of a large target population pool between 25 to 65 years in China and India and improving standards of living in the region
Some of the key players operating in the global market include Allergan, Inc.; Alma Laser; Cynosure; Galderma S.A.; Lumenis; Johnson and Johnson; Solta Medical, Inc.; and Syneron Medical Ltd.

Agriculture Equipment Market Size Worth $244.2 Billion By 2025

The global agriculture equipment market size is expected to reach USD 244.2 billion by 2025, expanding at a CAGR of 8.9% from 2019 to 2025, according to a study conducted by Grand View Research, Inc. Rising population has escalated demand for food and has pressurized the agriculture sector to be increasingly efficient and productive. Additionally, increased mechanization in the agriculture sector, rise in demand for agricultural products, and need for profitability and operational efficiency are some of the factors anticipated to drive the agricultural machinery market demand over the forecast period.

Rise in adoption of technology-driven equipment and machinery such as robotics is also anticipated to drive the farm machinery market demand over the forecast years. Farmers in developed regions are adopting modern technologies such as drones, moisture sensors, GPS enabled devices, self-driving tractors, smart irrigation, and terrain contour mapping to increase farm yield and address soaring food demand. Such technological advancements are fuelling the espousal of farm equipment across the globe.

The farm machinery market is also estimated to be driven by increasing sales in developing nations such as India, China, and Brazil, as these countries continue to mechanize their agricultural sectors. Furthermore, strong economic growth and population expansion are expected to impose pressure on the agriculture sectors to be more competent, thus increasing sales.On the down side, high cost of agricultural machinery and financial crisis faced by farmers are some of the major challenges hindering market growth.

The agriculture equipment market is highly competitive and fragmented owing to the presence of few prominent players, along with several medium- and small-scale players accounting for the market share. The key players in the market include John Deere, AGCO, Mahindra & Mahindra, CNH Industrial N.V., Iseki & Co., Ltd., and Kubota.

Several leading vendors are investing in R&D in order to develop innovative equipment and maintain a strong foothold in the market. For instance, in April 2017, Mahindra & Mahindra Limited launched its 24hp 4WD small tractor. It has been available in the Indian market since April 2017. The tractor caters to row cropping and horticulture applications, is capable of lifting up to 750 kg, and is equipped with automatic depth & draft control (ADDC) features.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/agriculture-equipment-market

The global agricultural equipment market is expected to register a CAGR of 8.9% from 2019 to 2025, due to technological advancements in agriculture automation and robotics as well as ever-increasing population
Growing number of government initiatives in developing countries, especially China and India, to enhance agricultural productivity is expected to further spur sale of farm equipment over the forecast period
By product, the tractors segment held the dominant share of over 25.0% in 2018, which is accredited to the fact that farmers are increasingly preferring tractors to increase production and restrict dependency on farm labor
On the basis of application, the harvesting and threshing segment is anticipated to witness significant growth over the forecast period and is expected to exceed a CAGR of 10.0% from 2019 to 2025
The Asia Pacific market is projected to expand at a CAGR of over 9.0%, owing to its existing and improving infrastructure levels, alternative sales channels, and government support
Key players in the market include John Deere, AGCO, Mahindra & Mahindra, CNH Industrial N.V., Iseki & Co., Ltd., and Kubota.

Tissue Diagnostics Market Worth $6.6 Billion By 2027

The global tissue diagnostics market size is anticipated to reach USD 6.6 billion by 2027, growing at a CAGR of 5.9% during the forecast period, according to a new report by Grand View Research, Inc. Accelerating demand for automated tissue diagnostic systems due to the lack of skilled pathologists has driven the market. The advent of advanced imaging techniques, such as autofluorescence, that minimize the need for invasive diagnostics further supplement market growth.

The digitalization of tissue diagnostic techniques has resulted in the improvement of workflows and better patient care. Ongoing strategic models taken-up by key companies to enhance the efficiency of diagnostics also drives the market. For instance, in December 2019, Philips collaborated with Paige to provide clinical-grade artificial intelligence-based solutions to pathology laboratories. This enhanced the speed and accuracy of cancer diagnostics in laboratories.

Tissue diagnostic techniques, such as immunohistochemistry (IHC) or in situ hybridization, are used in companion diagnostics (CDx) to determine the quantity of a target analyte present in the sample. Introduction of CDx tests, such as the launch of the VENTANA HER2 Dual ISH CDx

Click the link below:
https://www.grandviewresearch.com/industry-analysis/tissue-diagnostics-market

Further key findings from the report suggest:

IHC tests are highly adopted as these tests are specific and helpful in identifying the variations between different types of cancer, resulting in the largest revenue share
A rise in the investments for the development of advanced infrastructure to digitalize images is anticipated to drive the digital pathology segment with the fastest CAGR.
Moreover, an increase in the demand for automated modalities owing to a dearth of skilled pathologists further compliments this growth
A large number of breast cancer cases coupled with a rise in the application of digital image processing techniques on histopathological samples for breast cancer detection contributes to the largest share of breast cancer
Prostate cancer is anticipated to register lucrative growth owing to the extensive ongoing research pertaining to early diagnosis and prevention of this disease
Hospitals dominated the market in terms of revenue share due to the high adoption of tissue diagnostics solutions. These solutions provide accurate results in minimal time than conventional testing procedures
North America accounted for the largest revenue share owing to increasing collaborations between pharmaceutical and biotech firms to expand their product offerings
The requirement of better laboratory management systems, growing demand for novel patient care facilities, and favorable regulatory framework, boost the Asia Pacific market at a lucrative pace
Abbott, QIAGEN, Roche, Siemens, Danaher, Thermo Fisher, and Merck are some key participants operating in the tissue diagnostics market
Key vendors are engaged in novel product developments, partnership, and acquisition models to maintain their revenue share in the market.

Hemoglobinopathies Market Worth $12.6 Billion By 2026

The global hemoglobinopathies market size is expected to reach USD 12.6 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 10.2% during the forecast period.

Rising prevalence of hemoglobin disorders such as Sickle Cell Disease (SCD), thalassemia, Hb C, and Hb E is estimated to be a high impact rendering driver for the market. According to the World Health Organization (WHO), hemoglobin disorders are endemic in over 60% of 229 countries affecting over 70% of births. It is also reported that minimum 5% of the world population are carriers of significant hemoglobin variation.

Prevalence of hemoglobinopathies is high in low-income countries from regions, such as Sub-Saharan region and South-east Asia. 85% of the affected population in U.S. and Europe has ancestral base in these regions.

Governments are collaborating with local institutes to undertake awareness programs for curbing the effect of hemoglobinopathies-related mortality rate. For instance, Sickle Cell Disease Coalition (SCDC) was founded by The American Society of Hematology (ASH) in 2016 to promote awareness for the condition and enhance outcomes for individuals.

Insufficient healthcare infrastructure and low levels of disease diagnosis and treatments are some of the key factors contributing to the increase in target population in low-income regions such as South-east Asia, Mediterranean basin, and Africa.

North America led the overall hemoglobinopathies market in terms of revenue in 2018. Growing prevalence of blood disorders, favorable government programs, and high level of awareness among healthcare professionals and patients for hemoglobinopathies-related genetic testing, are the factors attributed to the growth.

Asia Pacific is expected to witness lucrative growth over the forecast period owing to the presence of high unmet clinical needs, improving healthcare infrastructure, and rising economic levels. Moreover, introduction of low-cost diagnostic alternatives for hemoglobinopathies is likely to further boost the growth.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/hemoglobinopathies-market

Further key findings from the report suggest:

SCD segment held the largest market share in 2018 owing to rising prevalence of sickle cell disease and presence of strong product pipeline such as LentiGlobin
Genetic testing for diagnosis of sickle cell disorders is expected to witness lucrative growth over the forecast period. Increasing awareness coupled with rising government programs is anticipated to enhance the usage rates for diagnostic tests pertaining to SCD
Pre-implant genetic diagnosis is estimated to witness lucrative CAGR of over 8.0% during the forecast period owing to rising awareness levels among the population and increasing healthcare expenditure
Blood transfusion was the largest therapy segment for hemoglobinopathies, owing to high acceptance of this treatment option and significant success rate
Key market players include Gamida Cell; Alnylam Pharmaceuticals; Sanofi; Sangamo Therapeutics Inc.; Global Blood Therapeutics; bluebird bio Inc.; Emmaus Life Sciences Inc.; Prolong Pharmaceuticals; and Celgene Corporation

3D Bioprinting Market Size Worth $4.2 Billion By 2027

The global 3D bioprinting market size is expected to reach USD 4.2 billion by 2027, expanding at a CAGR of 17.4%, according to a new report by Grand View Research, Inc. Rising prevalence of COVID-19 cases and increasing prevalence of chronic diseases are some of the major factors contributing towards market growth.

The COVID-19 epidemic is ever increasing since it was first identified in China in December 2019. Until May 26, 2020, more than 4.8 million cases of COVID-19 were reported globally, with more than 318,465 deaths, across 185 countries and territories including all 50 states of the United States. This pandemic has fast tracked the development of vaccine and drug testing, as scientists are using newer technologies to enable safety testing in people soon after preclinical phase is completed.

In the meantime, various 3D bioprinting companies are focused on research and development of artificial tissues. With the help of U-FAB, and other bioprinting technologies, CLECELL company has created respiratory epithelium artificial tissue which will help to prevent infection and tissue injury through the use of the mucociliary elevator. This pandemic has not only affected the well-being of people, but has also affected the economy, and various other healthcare infrastructures worldwide. This has severely disrupted the medical devices and pharmaceutical supply chains across the world. In such critical situation, various 3D bioprinting companies have created a global movement to supply emergency medical equipment such as ventilators, and personal protection equipment (PPE), to the healthcare workers.

North America held the highest share of the market, accounting for about 33.1% of the market share in 2019. Increasing adoption of 3D bioprinting for the production of medical products is expected to be one of the major factors contributing to market growth in this region. Whereas, Asia Pacific is anticipated to witness increased technological development in pharmaceutical and biopharmaceutical sector.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/3d-bioprinting-market

Further key findings from the report suggest:

The medical segment dominated the market with a share of 21.1% in 2019 due to the increasing investment made in R&D
The magnetic levitation segment is anticipated to witness the highest CAGR of 8.9% over the forecast period due to technological development, and increasing adoption of magnetic levitation technique by various innovators
North America dominated the market in 2019. Growing government expenditure on healthcare industry is one of the major factors driving the market in this region
Few of the key market players include 3D Systems; Organovo; CELLINK; Envision TEC; Materialise NV; Bio3D Technologies; Oceanz 3D printing & Additive Manufacturing; Solidscape; Stratasys Ltd.; and Voxeljet.

Medical Imaging Market Size Worth $28.83 Billion By 2027

The global medical imaging market size is expected to reach USD 28.83 billion by 2027, according to a new report published by Grand View Research, Inc. It is projected to register a CAGR of 4.0% during the forecast period. Increasing demand for advanced diagnostic systems in developing countries and rising collaborations among market players are the factors driving the growth.

Developing countries have shown a surge in the volume of imaging procedures in the past few years. The low density of installed imaging systems in these regions is expected to provide significant growth potential during the forecast period. Favorable government policies and booming medical tourism in these countries are expected to attract global market players toward untapped markets.

Integration of multiple imaging modalities is expected to play an important role in market growth. These systems have accurate diagnostic capabilities and are available at affordable prices. The integration of imaging modalities with surgical suites is anticipated to open a new avenue for the medical/diagnostic imaging market at a global level in the forthcoming years.

Development of portable diagnostic tools is important to expand the applications of imaging devices in ambulatory care, clinics, and emergency care departments. Handheld ultrasound devices provide quick and safer images that are critical in emergency care. Ongoing trials and studies to explore the potential of MRI technology for early detection of neurological conditions are showing positive results. The development of new radiofrequency coils is anticipated to expand these applications during the forecast period.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/medical-imaging-systems-market

Further key findings from the report suggest:

Ultrasound captured the largest market share in 2019 and is expected to dominate throughout the forecast period
Computed tomography is expected to expand at the fastest CAGR during the forecast period
Rapid technological advancements, such as the development of hybrid imaging modalities and integration of Artificial Intelligence (AI) is anticipated to fuel growth of the CT segment
Hospital segment is currently dominating the medical imaging market for diagnostic imaging due to blooming healthcare service industry in developing countries
Ambulatory care centers segment is anticipated to report the fastest growth during the forecast period
North America captured the largest medical/diagnostic imaging market share in 2019

Immunoprotein Diagnostic Testing Market Worth $10.3 Billion By 2025

The global immunoprotein diagnostic testing market size is anticipated to reach USD 10.3 billion by 2025, according to a new report by Grand View Research, Inc. This growth can be attributed to the rising incidence of chronic diseases.

According to American Heart Association’s 2017 statistics, nearly 790,000 people experience heart attack every year in the U.S. In addition, stroke is responsible for 1 in every 20 deaths in the U.S. Hence, WHO is also taking initiatives to reduce the risk of cardiovascular diseases. As a result of the aforementioned factors, the demand for immunoprotein diagnostics is expected to rise in order to facilitate rapid diagnosis.

According to WHO, nearly 1.69 million deaths due to lung cancer were registered in 2015 throughout the world. Hence, fast and accurate diagnosis of such chronic diseases has become important to reduce the high mortality rate. Immunoprotein diagnostic devices and reagents have proved to be highly effective in rapidly detecting chronic diseases.

Technological advancements in the field of immunoprotein diagnostics have led to introduction of novel products. For instance, LIAISON XL, manufactured by DiaSorin, is a fully automated chemiluminescence analyzer that facilitates complete sample processing. It also measures and evaluates testing samples, thereby, enhancing the efficiency and throughput of the system.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/immunoprotein-diagnostic-testing-industry

Further key findings from the study suggest:

In 2016, immunoglobulin tests dominated the market owing to their frequent usage by healthcare professionals for diagnosing infectious or autoimmune disorders
C-Reactive Protein (CRP) tests held a significant market share in 2016 due to the broad product portfolio of these assays and reagents
Infectious disease testing held largest market share in 2016 owing to the increasing prevalence of infectious diseases and high applications of immunoprotein tests
Enzyme-based immunoassays dominated the market in 2016 due to their frequent usage and availability of large number of products that possess this technology
Chemiluminescence assay is anticipated to witness highest growth over the forecast period due to its high sensitivity and specificity
North America dominated the market in 2016 due to rising prevalence of cancer & increase in mortality due to cancer-related diseases and favorable healthcare reimbursement scenario in the U.S.
Some of the key players of immunoprotein diagnostic testing market are Bio-Rad Laboratories, Inc.; F. Hoffmann-La Roche AG; Abbott Laboratories; Enzo Biochem, Inc.; Thermo Fisher Scientific, Inc.; DiaSorin S.p.A; bioMérieux SA; and Siemens Healthcare GmbH